Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, phase II clinical trial.

ABSTRACT:

Background

Pancreatic adenocarcinoma carries a grim prognosis, and there are few recognized effective second-line treatment strategies. We attempted to evaluate the efficacy and safety of a combination of S-1, sintilimab, and anlotinib as a second-line treatment in pancreatic cancer patients with liver metastasis.

Methods

Pancreatic cancer patients with liver metastases were recruited. S-1 was administered orally at 25 mg/m² bid, anlotinib was administered orally at 12 mg qd from day 1 to day 14, and sintilimab was administered intravenously at 200 mg on day 1. This method was repeated every 21 days, and the therapeutic effect was evaluated every 3 cycles. The primary outcome was the objective response rate (ORR).

Results

Overall, 23 patients were enrolled

SUBMITTER: Qiu X 

PROVIDER: S-EPMC10867188 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature